The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ALLAKOS INC COM 01671P100   77,318 17,733 SH   SOLE   17,733 0 0
COMPASS THERAPEUTICS INC COM 20454B104   138,220 43,466 SH   SOLE   43,466 0 0
ELEVATION ONCOLOGY INC COM 28623U101   33,022 21,725 SH   SOLE   21,725 0 0
MOLECULAR TEMPLATES INC COM 608550109   985,436 2,052,991 SH   SOLE   2,052,991 0 0
REZOLUTE INC COM NEW 76200L309   2,611,555 1,318,967 SH   SOLE   1,318,967 0 0
SAVARA INC COM 805111101   16,026,005 4,980,804 SH   SOLE   4,980,804 0 0
XERIS BIOPHARMA HOLDINGS INC COM 98422E103   14,781,830 5,641,920 SH   SOLE   5,641,920 0 0